http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014101036-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 |
| filingDate | 2011-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014101036-A |
| titleOfInvention | STABILIZED VORICONAZOLE COMPOSITION |
| abstract | 1. The use of lactose as a means to stabilize the composition, in particular, the lyophilized composition, comprising a mixture of voriconazole and hydroxypropyl beta-cyclodextrin. 2. The use according to claim 1, in which the stabilizing amount of lactose, in terms of lactose monohydrate, is at least 3, preferably from 4 to 10 parts by weight relative to voriconazole. A method for stabilizing a composition comprising a mixture of voriconazole and hydroxypropyl beta-cyclodextrin, the method comprising the steps of providing an aqueous solution comprising voriconazole and hydroxypropyl beta-cyclodextrin, preferably at a concentration of at least 10 mg / ml voriconazole, - adding a stabilizing amount of lactose to the specified aqueous solution and, optionally, lyophilizing the resulting stabilized composition. 4. A stabilized composition for intravenous administration of voriconazole, comprising one part by weight of voriconazole, 10-30 parts by weight of 2-hydroxypropyl-beta-cyclodextrin, and at least 3, preferably from 4 to 10 parts by weight of lactose, in terms of lactose monohydrate. 5. The composition according to claim 4, combined with an aqueous diluent, giving a stabilized solution of voriconazole, including voriconazole at a concentration of 10 mg / ml, hydroxypropyl beta-cyclodextrin at a concentration of 100-300 mg / ml and lactose at a concentration of at least 30 mg / ml, preferably between 40 and 100 mg / ml (in terms of lactose monohydrate) .6. The composition according to claim 4 or 5, in which 2-hydroxypropyl-beta-cyclodextrin is a highly substituted 2-hydroxypropyl-beta-cycle� |
| priorityDate | 2011-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.